Phase 3 SELVA study evaluating QTORIN™ rapamycin 3.9% anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic ...
Bright Minds Biosciences Inc. ("Bright Minds" or the "Company") today closed its recently announced public offering of 1,945,000 common shares in the capital of the Company (the "Common Shares") at a ...
LEXINGTON, Mass. and AMSTERDAM, Jan. 09, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing ...
Detailed price information for Abpro Holdings Inc (ABP-Q) from The Globe and Mail including charting and trades.
Phase 3 SELVA study evaluating QTORIN rapamycin 3.9% anhydrous gel (QTORIN rapamycin) for microcystic lymphatic malformations (microcystic LMs) remains on track, with topline results anticipated in Ma ...
LEXINGTON, Mass. and AMSTERDAM, Jan. 09, 2026N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced a Type A mee ...
Times-Standard on MSN
Caltrans to close one lane of traffic following flood-related ‘movement’ of Fernbridge
Caltrans has announced a one-day lane closure on Fernbridge scheduled for next week. Drivers can expect 5- to 10-minute ...
Learn about commercial construction, its phases, key players, and how ConstructConnect® supports the industry from ...
SAN DIEGO, CA / ACCESS Newswire / January 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or ...
For further information on Bright Minds, investors should review the Company’s annual Form 40-F filing with the United States Securities and Exchange Commission available at www.sec.gov and home ...
Insufficient architectural integrity is a major AI blocker, forcing many organizations to prioritize speed over foundational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback